PLG Nanoparticle-Based Antigen Delivery for The Tolerogenic Treatment of Autoreactive T & B Cell Responses in a Mouse Model of Neuromyelitis Optica (NMO)

Time: 1:00 pm
day: Day Two


  • Review the mechanisms of PLG nanoparticle-induced tolerance and its
  • translational potential in a Phase 1/2a clinical trial in celiac disease
  • Describe the requirements for induction of a new mouse model of NMO
  • Decipher the efficacy of tolerance using PLG nanoparticle